FDA's commitment to transparency

被引：0

作者：

Guharoy, Roy ^{[1
,2
]}

Krenzelok, Edward ^{[3
]}

机构：

[1] Baptist Hlth, Dept Pharm, Montgomery, AL 36117 USA

[2] Univ Massachusetts, Sch Med, Montgomery, AL 36117 USA

[3] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA

来源：

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2021年 / 78卷 / 17期

关键词：

D O I：

10.1093/ajhp/zxab053

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1550 / 1551

页数：2

共 50 条

[21] FDA transparency rules could hit small companies hardest
Malorye Allison
[J]. Nature Biotechnology, 2010, 28 : 767 - 768
[22] FDA faces congressional probes and more transparency and organizational changes
Wechsler, Jill
[J]. FORMULARY, 2011, 46 (02) : 66 - 67
[23] FDA transparency rules could hit small companies hardest
Allison, Malorye
[J]. NATURE BIOTECHNOLOGY, 2010, 28 (08) : 767 - 768
[24] Clinical Trial Transparency: The FDA Should and Can Do More
Kapczynski, Amy
Kim, Jeanie
[J]. JOURNAL OF LAW MEDICINE & ETHICS, 2017, 45 : 33 - 38
[25] Medication errors in community pharmacies: The need for commitment, transparency, and research
Hong, Kyungwan
Hong, Yoon Duk
Cooke, Catherine E.
[J]. RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2019, 15 (07): : 823 - 826
[26] SOEs' commitment to transparency: Voluntary disclosure as a driver of mandatory disclosure
Lopez, Estibaliz Biedma
Jorge, Manuel Larran
Aguilar, Nieves Gomez
Carril, Maria C. Conesa
[J]. ANNALS OF PUBLIC AND COOPERATIVE ECONOMICS, 2024, 95 (03) : 883 - 917
[27] Transparency Initiative by the FDA's Center for Drug Evaluation and Research (CDER): Two qualitative studies of Public Perceptions
Chakraborty, Sweta
Lofstedt, Ragnar
[J]. EUROPEAN JOURNAL OF RISK REGULATION, 2012, 3 (01) : 57 - 71
[28] Transparency and Trust as Antecedents to Perceptions of Commitment to Stated Diversity Goals
Pepper, Molly B.
Tredennick, Linda
Reyes, Raymond F.
[J]. JOURNAL OF DIVERSITY IN HIGHER EDUCATION, 2010, 3 (03): : 153 - 162
[29] US FDA releases report outlining commitment to personalized medicine
Wilson, Hannah
[J]. PERSONALIZED MEDICINE, 2014, 11 (01) : 8 - 8
[30] Transparency Initiative to provide more information on FDA regulation and drug development
Wechsler, Jill
[J]. FORMULARY, 2010, 45 (07) : 232 - 233

← 1 2 3 4 5 →